de Isla LP, et al. - In order to detect familial hypercholesterolaemia (FH) patients who were more likely to derive the greatest benefit from proprotein convertase subtilisin/kexin-type 9 (PCSK9) mAb, researchers estimated the number needed to treat (NNT) at different risk thresholds and baseline LDL-cholesterol (LDL-C) by using the SAFEHEART Risk Equation (RE). FH cases (aged 18 years or older) on maximum tolerated lipid lowering therapy constituted 2,153 of the total SAFEHEART population. For those with 5-year risk of ≥1 to ≥5, NNTs were dependent on both, baseline predicted risk and baseline LDL-C level ranging from 44 to 17. Among those with 5-year risk of ≥5% and LDL-C ≥160 mg/dl, the smallest NNT (12) was found. Similar findings were obtained with the Cholesterol Treatment Trialists’ criteria. Overall, the possible utility of the SAFEHEART-RE was suggested, as a quantitative tool, for rationalising the selection of FH patients who might derive greater absolute benefits from PCSK9 mAb.